Nexalin Technology, Inc. - Warrant (NQ: NXLIW )

0.1025 UNCHANGED

Last Price Updated: 10:22 AM EDT, Sep 19, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	0.1025
Bid (Size)	0.0751 (10)
Ask (Size)	0.1245 (1)
Prev. Close	0.1025
Today's Range	0.1025 - 0.1025
52wk Range	0.0075 - 0.5600
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

September 05, 2024

Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

July 18, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Performance

YTD	+1266.67%	+1266.67%
1 Month	-15.22%	-15.22%
3 Month	-74.38%	-74.38%
6 Month	+145.22%	+145.22%
1 Year	+310.00%	+310.00%

More News

Nexalin Technology Announces Closing of $5.2 Million Public Offering

July 01, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

June 27, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

June 20, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

June 13, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

June 06, 2024

Via ACCESSWIRE

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

June 04, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

June 03, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

May 22, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

May 09, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

April 25, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

April 09, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

April 04, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

April 02, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

March 28, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

March 14, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

March 13, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

March 06, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

February 08, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

January 23, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Unveils Next-Generation HALO™ Clarity

January 11, 2024

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

December 18, 2023

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

October 25, 2023

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

October 16, 2023

From Nexalin Technology, Inc.

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.